Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology
Authors:
- 10 January 2022
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (10) , 4687-4694
Abstract
Background and Aims The treatment of chronic pouchitis remains a challenge due to the paucity of high-quality studies. We aimed to provide guidance for clinicians on the appropriateness of medical and surgical treatments in chronic pouchitis. Methods Appropriateness of medical and surgical treatments in patients with chronic pouchitis was considered in 16 scenarios incorporating presence/absence of four variables: pouchitis symptoms, response to antibiotics, significant prepouch ileitis, and Crohn’s disease (CD)-like complications (i.e., stricture or fistula). Appropriateness of permanent ileostomy in patients refractory to medical treatments was considered in eight additional scenarios. Using the RAND/UCLA appropriateness method, international IBD expert panelists rated appropriateness of treatments in each scenario on a 1–9 scale. Results Chronic antibiotic therapy was rated appropriate only in asymptomatic antibiotic-dependent patients with no CD-like complications and inappropriate in all other scenarios. Ileal-release budesonide was rated appropriate in 6/16 scenarios including patients with significant prepouch ileitis but no CD-like complications. Probiotics were considered either inappropriate (14/16) or uncertain (2/16). Biologic therapy was considered appropriate in most scenarios (14/16) and uncertain in situations where significant prepouch ileitis or CD-like complications were absent (2/16). In patients who are refractory to all medications, permanent ileostomy was considered appropriate in all scenarios (7/8) except in asymptomatic patients with no CD-like complications. Conclusions In the presence of significant prepouch ileitis or CD-like complications, chronic antibiotics and probiotics are inappropriate. Biologics are appropriate in all patients except in asymptomatic patients with no evidence of complications. Permanent ileostomy is appropriate in most medically refractory patients.Keywords
Funding Information
- AbbVie
- Takeda Pharmaceuticals U.S.A.
- Pfizer
This publication has 28 references indexed in Scilit:
- Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of ResultsClinical Gastroenterology and Hepatology, 2016
- Systematic review: outcomes and post‐operative complications following colectomy for ulcerative colitisAlimentary Pharmacology & Therapeutics, 2016
- Outcomes with Anti-Tumour Necrosis Factor-Alpha Therapy and Serology in Patients withDenovoCrohn’s Disease After Ileal Pouch Anal AnastomosisJournal of Crohn's and Colitis, 2016
- Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2016
- Quality of life after proctocolectomy and ileal pouch-anal anastomosis in patients with ulcerative colitisInternational Journal of Colorectal Disease, 2013
- Pouchitis: What Every Gastroenterologist Needs to KnowClinical Gastroenterology and Hepatology, 2013
- Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based StudiesGastroenterology, 2013
- Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic eraAlimentary Pharmacology & Therapeutics, 2013
- Ileal Pouch Anal AnastomosisAnnals of Surgery, 2013
- Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome.2001